Cargando…

Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer

BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatogai, Ken, Yano, Tomonori, Kojima, Takashi, Onozawa, Masakatsu, Fujii, Satoshi, Daiko, Hiroyuki, Yoda, Yusuke, Hombu, Takuya, Doi, Toshihiko, Kaneko, Kazuhiro, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769588/
https://www.ncbi.nlm.nih.gov/pubmed/26922374
http://dx.doi.org/10.1186/s13014-016-0604-z
_version_ 1782418131154632704
author Hatogai, Ken
Yano, Tomonori
Kojima, Takashi
Onozawa, Masakatsu
Fujii, Satoshi
Daiko, Hiroyuki
Yoda, Yusuke
Hombu, Takuya
Doi, Toshihiko
Kaneko, Kazuhiro
Ohtsu, Atsushi
author_facet Hatogai, Ken
Yano, Tomonori
Kojima, Takashi
Onozawa, Masakatsu
Fujii, Satoshi
Daiko, Hiroyuki
Yoda, Yusuke
Hombu, Takuya
Doi, Toshihiko
Kaneko, Kazuhiro
Ohtsu, Atsushi
author_sort Hatogai, Ken
collection PubMed
description BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective study to clarify the risk factors for local recurrence along with the long term results after SET for recurrent lesions after definitive CRT for ESCC. METHODS: We enrolled 77 consecutive patients who underwent EMR or PDT for local recurrence without any metastasis after definitive CRT at our institution. We evaluated the local efficacy, local recurrence-free survival (LRFS), and overall survival (OS), and investigated the risk factors associated with survival outcome using a multivariate analysis. RESULTS: The complete resection rate of EMR was 84.6 % (33/39), and the complete response rate for PDT was 65.8 % (25/38). Twenty-two patients (28.6 %) exhibited local recurrence without metastasis. Thirty-four patients (44.2 %) were alive at 5 years after undergoing only initial SET or with repeated SET. The 5-year LRFS rate was 59.6 %, and the presence of lesions occupying an esophageal circumference of 1/4 or larger was the only significant risk factor (HR: 3.10, 95 % CI: 1.35–7.15, P = 0.008). The 5-year OS rate was 48.4 %, and an advanced T factor before CRT was marginally associated with a poor OS (HR: 1.96, 95 % CI: 0.98–3.92, P = 0.055). CONCLUSIONS: SET enabled a preferable local control and survival outcome for patients with local recurrence after definitive CRT for ESCC. Careful endoscopic follow-up is needed for patients with a large lesion before SET and those with an advanced T factor before CRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0604-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4769588
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47695882016-02-28 Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer Hatogai, Ken Yano, Tomonori Kojima, Takashi Onozawa, Masakatsu Fujii, Satoshi Daiko, Hiroyuki Yoda, Yusuke Hombu, Takuya Doi, Toshihiko Kaneko, Kazuhiro Ohtsu, Atsushi Radiat Oncol Research BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective study to clarify the risk factors for local recurrence along with the long term results after SET for recurrent lesions after definitive CRT for ESCC. METHODS: We enrolled 77 consecutive patients who underwent EMR or PDT for local recurrence without any metastasis after definitive CRT at our institution. We evaluated the local efficacy, local recurrence-free survival (LRFS), and overall survival (OS), and investigated the risk factors associated with survival outcome using a multivariate analysis. RESULTS: The complete resection rate of EMR was 84.6 % (33/39), and the complete response rate for PDT was 65.8 % (25/38). Twenty-two patients (28.6 %) exhibited local recurrence without metastasis. Thirty-four patients (44.2 %) were alive at 5 years after undergoing only initial SET or with repeated SET. The 5-year LRFS rate was 59.6 %, and the presence of lesions occupying an esophageal circumference of 1/4 or larger was the only significant risk factor (HR: 3.10, 95 % CI: 1.35–7.15, P = 0.008). The 5-year OS rate was 48.4 %, and an advanced T factor before CRT was marginally associated with a poor OS (HR: 1.96, 95 % CI: 0.98–3.92, P = 0.055). CONCLUSIONS: SET enabled a preferable local control and survival outcome for patients with local recurrence after definitive CRT for ESCC. Careful endoscopic follow-up is needed for patients with a large lesion before SET and those with an advanced T factor before CRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0604-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-27 /pmc/articles/PMC4769588/ /pubmed/26922374 http://dx.doi.org/10.1186/s13014-016-0604-z Text en © Hatogai et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hatogai, Ken
Yano, Tomonori
Kojima, Takashi
Onozawa, Masakatsu
Fujii, Satoshi
Daiko, Hiroyuki
Yoda, Yusuke
Hombu, Takuya
Doi, Toshihiko
Kaneko, Kazuhiro
Ohtsu, Atsushi
Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title_full Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title_fullStr Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title_full_unstemmed Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title_short Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
title_sort local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769588/
https://www.ncbi.nlm.nih.gov/pubmed/26922374
http://dx.doi.org/10.1186/s13014-016-0604-z
work_keys_str_mv AT hatogaiken localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT yanotomonori localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT kojimatakashi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT onozawamasakatsu localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT fujiisatoshi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT daikohiroyuki localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT yodayusuke localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT hombutakuya localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT doitoshihiko localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT kanekokazuhiro localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer
AT ohtsuatsushi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer